BMS, Pfizer secure victory over generic makers

In a victory for Bristol-Myers Squibb (BMS) and Pfizer, a US federal judge has affirmed patents covering blood-thinner Eliquis (apixaban).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

BMS, Pfizer win patent dispute over blockbuster drug, Eliquis

6 September 2021 In a victory for Bristol-Myers Squibb and Pfizer, the US Court of Appeals for the Federal Circuit has affirmed the validity of a pair of patents covering blood clot treatment, Eliquis.

Biotechnology

Pfizer to collaborate with Imcyse on new immunotherapy programme

5 February 2021 Pfizer has struck a research and licensing agreement with Belgium biopharmaceutical company Imcyse to develop treatments for rheumatoid arthritis using Imotopes - Imcyse’s platform of immunotherapeutics based on synthetic peptides.

Generics

Sigmapharm to appeal Pfizer and BMS’ Eliquis win

3 September 2020 Generics maker Sigmapharm Laboratories is appealing against a court win for Pfizer and Bristol Myers Squibb over patents for blood-thinner Eliquis.

More features

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

BMS, Pfizer secure victory over generic makers

More on this story

Editor's picks

Editor's picks

More features